Presentations 2001
The Australian ASHM Conference, Melbourne, 2001
1. Cardiovascluar risk in Hiv patients - association with antiretroviral therapy. The DAD Study. M Law, N Friis-møller, P Reiss, A d´Arminio Monforte, M Rickenbach, R Thiebaut, C Pradier, L Morfeldt, G Calvo, G Bartsch, S De Wit, AN Phillips, JD Lundgren for the DAD study group.
8th Conference on retroviruses and opportunistic infections, Chicago, February 2001
1. Changes in cause of death across Europe. A Mocroft, R Brettle, O Kirk, A Blaxhult, JM Parkin, F Antunes, P Francioli, A d´Arminio Monforte, AN Phillips, and JD Lundgren. (EuroSIDA 298)
2. Virological and clinical outcome of NNRTI-containing regimens for 1932 patients in EuroSIDA. AN Phillips, C Pradier, A Lazzarin, B Clotet, F Goebel, P Hermans, F Antunes, B Ledergerber, O Kirk, and J Lundgren.
(EuroSIDA 324)
5th International Workshop on HIV observational databases, Monte Carlo, April 2001
1. The influence of the analytic method used in clinical trial of HAART. Results form EuroSida and randomised clinical trials (RCT). O Kirk and J Lundgren.
(EuroSIDA oral ses. 2)
2. Predictors of clinical outcome – how different are they form predictors of virological outcome? JD Lundgren
(EuroSIDA oral ses 3)
3. The DAD-study: Data collection on adverse events of anti-HIV drugs. DAD study group
(DAD oral ses.6)
4. Changes in viral load in people with virological failure who remain on the same HAART regimen. A Cozzi-Lepri, A Phillips, V Miller, J Lundgren.
(EuroSIDA oral ses. 4)
5. Design of safety reports from the EuroSIDA study. N Friis-Møller, O Kirk, JD Lundgren. (EuroSIDA poster ses.6)
The 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, July 2001
1. Non-Hodgkin lymphoma (NHL) among HIV-infected patients in the era of highly active antiretroviral therapy (HAART). O Kirk, A Mocroft, S Barton, C Pedersen, P Skinhøj, V Miller, J Lundgren.
(EuroSIDA 69)
2. Soluble urokinase plasminogen activator receptor (suPAR) – A potential marker for responsiveness to HAART? K Jensen, C Madsen, O Kirk, A Meyer, J Parner, J Lundgren, K Krogsgaard, J Eugen-Olsen.
(Diverse 281)
8th European Conference on Clinical Aspects and Treatment of HIV-Infection, Athens, October 2001.
1. A randomised trial comparing continued indinavir vs switching to indinavir plus retonavir in HIV-patients having suppressed viral load with indinavir plus two nucleoside analogue reverse transcriptase inhibitors: The BEST study. J Gerstoft, J Mallolas, J Lundgren, G Faetkenheuer, A D´Arminio Monforte, F Antunes, P Reiss, JM Gatell.
(BEST 240)
2. A phase IV randomised open-label, multicentre trial to evaluate safety and efficacy of indinavir/ritonavir (800/100 mg bid) vs. saquinavir /ritonavir (1000/100 mg bid) in adult HIV-1 infection: The MaxCmin1 trial. UB Dragsted.
(MaxCmin1 407)
3. Factors affecting incidence of and survival after CMV end-organ disease in patients with AIDS in Europe. I Yust, P Reiss, D Turner, O Kirk, C Katlama, A Mocroft, J van Lunzen, M Burke, A Chiesi, JD Lundgren.
(EuroSIDA 521)
4. Cardiovascular risk-factors in HIV patients - association with antiretroviral therapy. The DAD Study. N Friis-Møller, P Reiss, O Kirk, A D'Arminio Monforte, M Rickenbach, R Thiebaut, C Pradier, L Morfeldt, G Calvo, M Law, G Bartsch, S De Witt, AN Phillips, JD Lundgren for the DAD Study Group.
(DAD 408)
41st Interscience Conference on Antimicrobial agents and Chemotherapy, Chicago, December 2001.
1. Risks for cardiovascular disease (CVD) associated with antiretroviral therapy (ART). R Weber, N Friis-Møller, F Dabis, P Reiss, A D´Armino Monforte, G Calvo, C Pradier, L Morfeldt, M Law, A Phillips, JD Lundgren.
(DAD I-1326)
2. The DAD study: Data collection on adverse events of anti-HIV drugs. The DAD Study group
(Oral pres. ses. 6)
3. The Stability of the viral load in subjects with virological failure who remain on the same HAART regimen: The EuroSIDA study. JD Lundgren, A Cozzi-Lepri, V Miller, B Ledergerber, S Vella, J Weber, JN Bruun, O Kirk, B Clotet, A. Phillips.
(EuroSIDA I-1915)
Updated: 13 Dec 2005